Orphanet: Simple search

Search for a clinical trial

Other search option(s)

311 Result(s)

National clinical trial(s)

PMNN: Personalized Medicine for Membranous Nephropathy Faculté de médecine de Nice Sophia-Antipolis CHU Nice

A phase III, randomized, open-label active comparator-controlled multicenter study to evaluate efficacy and safety of obinutuzumab in patients with primary membranous nephropathy -ES Institution: Information not provided - ES

Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy - SE Institution: Information not provided - SE

A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN) (Phase II-III) Mayo Clinic

A Phase II open-label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with Alport syndrome with Col4A5 and Col4A3/4 nonsense mutation -AU Institution: Information not provided - AU

NOBLE: An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN - AT Institution: Information not provided - AT

VALIANT: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis - AT Institution: Information not provided - AT

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy - BE Cliniques Universitaires de Bruxelles - Hôpital Erasme Néphrologie

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE- LMU Klinikum der Universität München - Campus Großhadern LMU Klinikum

ACCOLADE: A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE- Institution: Information not provided - DE

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE- Medizinische Hochschule Hannover Medizinische Hochschule Hannover (MHH)

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE- Universitätsklinikum Essen

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE- Universitätsklinikum Carl Gustav Carus an der TU Dresden Universitätsklinikum Dresden

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE- Universitätsklinikum Schleswig-Holstein - Campus Lübeck

An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy -ES Institution: Information not provided - ES

NOBLE: An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN -ES Institution: Information not provided - ES

APPEAR-C3G: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy -ES Institution: Information not provided - ES

EPPIK: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases -ES Institution: Information not provided - ES

VALIANT: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis - ES Institution: Information not provided - ES

APPEAR-C3G: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy - CH Institution: Information not provided - CH

OL Extension Study of LNP023 in C3G-GB Institution: Information not provided - GB

A Phase II open-label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with Alport syndrome with Col4A5 and Col4A3/4 nonsense mutation -GB Institution: Information not provided - GB

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -GB St Bartholomew's Hospital, Barts and The London NHS Trust Barts & The London NHS Trust

AFFIRM-AL: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis - AT Institution: Information not provided - AT

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - BE Cliniques Universitaires de Bruxelles - Hôpital Erasme Service de Pneumologie

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - BE Cliniques universitaires Saint-Luc - UCLouvain Service de pneumologie

VAIN study: A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome - BE Universitair Ziekenhuis Brussel Nefrologie dienst / Nephrology department

SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE Ghent University Hospital - UZ Gent Department of Rheumatology

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)-CA Institution: Information not provided - CA

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy-CA Institution: Information not provided - CA

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)-CA Institution: Information not provided - CA

Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI- Turku University Hospital Turku PET CENTRE

AVADIS: Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis -FR CHU Grenoble Alpes - Site Nord - Hôpital Couple Enfant Clinique Universitaire de Médecine Vasculaire

SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis CHU de Rennes - Hôpital Pontchaillou Service de Radiologie et imagerie médicale - Imagerie thoracique et cardio-vasculaire

NEPHRUTIX - A prospective, randomised, double blind, placebo-controlled phase II/III study evaluating the efficacy of rituximab in the prevention of relapse of calcineurin inhibitors dependent idiopathic nephrotic syndrome of childhood - FR Institution: Information not provided - FR

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR Institution: Information not provided - FR

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis -FR Institution: Information not provided - FR

Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial - SCLERITA - SCLERITA Institution: Information not provided - FR

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis -FR Institution: Information not provided - FR

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous -FR Institution: Information not provided - FR

ITAC: Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease. AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière Département de Médecine Interne et Immunologie Clinique (DMIIC)

NEPHROMYCY - Cyclophosphamide versus mycophenolate mofetil for children with steroid-dependent idiopathic nephrotic syndrome : a multicenter randomized controlled trial (Phase III). CHU Paris - Hôpital Robert Debré Service de Néphrologie - Hémodialyse

COLCHI-RESIST: Study Of Colchicine Resistance In Familial Mediterranean Fever. Groupe hospitalier AP-HP.6 - Hôpital Tenon Service de médecine interne

AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR CHU de Limoges - Hôpital Dupuytren Service d'hématologie clinique et de thérapie cellulaire

AMYLCAR : Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries (Phase I) CHU de Toulouse - Hôpital Pierre-Paul Riquet Service de Médecine nucléaire

ADUSE: Subcutaneous Injections of Autologous Cultured Adipose-derived Stroma/ Stem Cells to Heal Refractory Ischemic Digital Ulcers in Patients With Scleroderma. CHU de Toulouse - Hôpital Rangueil Service de Médecine interne et immunologie clinique

SCLERADEC III : SCLERoderma and Adipose-DErived Stroma Cells (Phase II) CHU de Marseille - Hôpital Nord Service de Médecine Interne

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - DE Zentrum für Innere Medizin (Krehl-Klinik) Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

ReDox: A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - DE Zentrum für Innere Medizin (Krehl-Klinik) Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis -DE Zentrum für Innere Medizin (Krehl-Klinik) Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

PRESIDIO: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomyositis Institution: Information not provided - DE

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis - DE Institution: Information not provided - DE

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous - DE Institution: Information not provided - DE

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE Charité - Universitätsmedizin Berlin

wiRASSc: Influence of serial locoregional water-filtered infrared A radiation in addition to a multimodal standard therapy for systemic sclerosis and Raynaud's syndrome of the hands Kerckhoff-Klinik GmbH Abteilung für Rheumatologie und klinische Immunologie

SENSCIS (TM) Extension: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - DE Medizinische Hochschule Hannover Klinik für Pneumologie

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE Universitätsklinikum Essen Klinik für Neurologie

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE Universitätsklinikum Köln

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE Universitätsklinikum Münster

A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis Institute of Genomic Medicine and Rare Disorders, Semmelweis University Genetics Laboratory

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy - IE Beaumont Hospital Kidney Centre

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE St. Vincent's University Hospital CF Clinic

EYEGUARD-B: Studio randomizzato, in doppio cieco, controllato verso placebo, dell'efficacia di gevokizumab nel trattamento di pazienti affetti da uveite di Behcet Institution: Information not provided - IT

A phase 3, multicenter, randomized, doubleblind, placebo-controlled, parallel group study, followed by an active-treatment phase to evaluate the efficacy and safety of Apremilast (CC-10004) in the treatment of subjects with active Behçet's disease - IT Institution: Information not provided - IT

OFA3: Efficacy of humanized anti-CD20 antibodies (Ofatumumab) in the treatment of childhood steroid-dependent nephrotic syndrome and development of cell biomarkers predicting outcome Institution: Information not provided - IT

An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy - IT Institution: Information not provided - IT

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis - IT Institution: Information not provided - IT

Efficacy of monoclonal anti CD 20 antibodies in steroid and cyclosporin dependent nephrotic syndrome in children - IT IRCCS Ospedale Pediatrico Bambino Gesù - SEDE SAN PAOLO Laboratorio di Nefrologia - Divisione di Nefrologia e Dialisi

Five-year actively controlled clinical trial in new onset juvenile dermatomyositis IRCCS Istituto G. Gaslini - Ospedale Pediatrico U.O. Pediatria II

A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - IT Fondazione IRCCS Policlinico San Matteo Dipartimento di Medicina Molecolare

ASTIS: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis (Phase III) - IT AOU Careggi Dipartimento di Biomedicina

A Phase II/III, randomized, double-blind, placebo-controlled study and open active-treatment extension study to assess the efficacy and safety of the branch chain amino acids (BCAAs) in polymyositis and dDermatomyositis. Institution: Information not provided - JP

Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever Institution: Information not provided - JP

Clinical trial of rituximab in interstitial lung disease secondary to systemic sclerosis Institution: Information not provided - JP

Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone Radboudumc - Radboud universitair medisch centrum Afdeling Nierziekten

Levamisole treatment for children with steroid sensitive nephrotic syndrome. An international multi-centre, double-blind, placebo-controlled, randomised trial Amsterdam UMC, locatie AMC Polikliniek Kindernefrologie

PMNN: Personalized Medicine for Membranous Nephropathy
Faculté de médecine de Nice Sophia-Antipolis

CHU Nice

A phase III, randomized, open-label active comparator-controlled multicenter study to evaluate efficacy and safety of obinutuzumab in patients with primary membranous nephropathy -ES
Institution: Information not provided - ES

Phase 2, Multicenter, Randomized, Open-label, Controlled, 2-arm Cross-over Study to Evaluate the Clinical Efficacy of a Renin Inhibitor, Aliskiren, Compared to an Angiotensin Converting Enzyme Inhibitor, Enalapril, in C3 Glomerulopathy - SE
Institution: Information not provided - SE

A Randomized Controlled Trial of Rituximab Versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (IMN) (Phase II-III)
Mayo Clinic

A Phase II open-label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with Alport syndrome with Col4A5 and Col4A3/4 nonsense mutation -AU
Institution: Information not provided - AU

NOBLE: An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN - AT
Institution: Information not provided - AT

VALIANT: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis - AT
Institution: Information not provided - AT

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Néphrologie

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE-
LMU Klinikum der Universität München - Campus Großhadern

LMU Klinikum

ACCOLADE: A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE-
Institution: Information not provided - DE

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE-
Medizinische Hochschule Hannover

Medizinische Hochschule Hannover (MHH)

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE-
Universitätsklinikum Essen

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE-
Universitätsklinikum Carl Gustav Carus an der TU Dresden

Universitätsklinikum Dresden

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -DE-
Universitätsklinikum Schleswig-Holstein - Campus Lübeck

An open-label, non-randomized extension study to evaluate the long-term efficacy, safety and tolerability of LNP023 in subjects with C3 glomerulopathy -ES
Institution: Information not provided - ES

NOBLE: An Open-Label, Randomized, Controlled, Phase 2 Study to Evaluate the Safety and Efficacy of Pegcetacoplan in the Treatment of Post-Transplant Recurrence of C3G or IC-MPGN -ES
Institution: Information not provided - ES

APPEAR-C3G: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy -ES
Institution: Information not provided - ES

EPPIK: A Phase 2, Open-Label, Single-Arm, Cohort Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Sparsentan Treatment in Pediatric Subjects with Selected Proteinuric Glomerular Diseases -ES
Institution: Information not provided - ES

VALIANT: A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis - ES
Institution: Information not provided - ES

APPEAR-C3G: A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy - CH
Institution: Information not provided - CH

OL Extension Study of LNP023 in C3G-GB
Institution: Information not provided - GB

A Phase II open-label pilot study to evaluate the safety and efficacy of subcutaneously administered ELX-02 in patients with Alport syndrome with Col4A5 and Col4A3/4 nonsense mutation -GB
Institution: Information not provided - GB

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy -GB
St Bartholomew's Hospital, Barts and The London NHS Trust

Barts & The London NHS Trust

AFFIRM-AL: A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, Efficacy and Safety Study of Birtamimab Plus Standard of Care vs. Placebo Plus Standard of Care in Mayo Stage IV Subjects with Light Chain (AL) Amyloidosis - AT
Institution: Information not provided - AT

A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD) - BE
Cliniques Universitaires de Bruxelles - Hôpital Erasme

Service de Pneumologie

A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants with Pulmonary Fibrosis - BE
Cliniques universitaires Saint-Luc - UCLouvain

Service de pneumologie

VAIN study: A Prospective Interventional Pilot Study on the Use of Valproic Acid for Treatment of Idiopathic Nephrotic Syndrome - BE
Universitair Ziekenhuis Brussel

Nefrologie dienst / Nephrology department

SENSCISTM-ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - BE
Ghent University Hospital - UZ Gent

Department of Rheumatology

A Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Focal Segmental Glomerulosclerosis (FSGS)-CA
Institution: Information not provided - CA

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy-CA
Institution: Information not provided - CA

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD)-CA
Institution: Information not provided - CA

Imaging of Active Granulomas With [18F]FDG and Selected Inflammatory PET Tracers in Pulmonary Sarcoidosis -FI-
Turku University Hospital

Turku PET CENTRE

AVADIS: Impact of Transcutaneous Auricular Vagus Nerve Stimulation on Digestive Symptoms in Systemic Sclerosis -FR
CHU Grenoble Alpes - Site Nord - Hôpital Couple Enfant

Clinique Universitaire de Médecine Vasculaire

SARCOLOWDOSE : Ultra-low Dose CT Scan and MRI in Thoracic Sarcoidosis
CHU de Rennes - Hôpital Pontchaillou

Service de Radiologie et imagerie médicale - Imagerie thoracique et cardio-vasculaire

NEPHRUTIX - A prospective, randomised, double blind, placebo-controlled phase II/III study evaluating the efficacy of rituximab in the prevention of relapse of calcineurin inhibitors dependent idiopathic nephrotic syndrome of childhood - FR
Institution: Information not provided - FR

An Open-Label, Dose-Escalation, Phase 1 Study of the Oral Formulation of MLN9708 Administered Weekly in Adult Patients With Relapsed or Refractory Light-Chain (AL) Amyloidosis Who Require Further Treatment - FR
Institution: Information not provided - FR

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis -FR
Institution: Information not provided - FR

Safety and efficacy of itacitinib in adults with systemic sclerosis: a phase II, randomized, controlled trial - SCLERITA - SCLERITA
Institution: Information not provided - FR

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants With Dermatomyositis -FR
Institution: Information not provided - FR

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous -FR
Institution: Information not provided - FR

ITAC: Multicenter, Randomized, Prospective Trial Comparing the Efficacy and Safety of Infliximab to That of Cyclophosphamide in Severe Behçet's Disease.
AP-HP.Sorbonne Université - Hôpital de la Pitié-Salpêtrière

Département de Médecine Interne et Immunologie Clinique (DMIIC)

NEPHROMYCY - Cyclophosphamide versus mycophenolate mofetil for children with steroid-dependent idiopathic nephrotic syndrome : a multicenter randomized controlled trial (Phase III).
CHU Paris - Hôpital Robert Debré

Service de Néphrologie - Hémodialyse

COLCHI-RESIST: Study Of Colchicine Resistance In Familial Mediterranean Fever.
Groupe hospitalier AP-HP.6 - Hôpital Tenon

Service de médecine interne

AmyDara: A Multicentre Open Label Phase II Study of Daratumumab in AL Amyloidosis Patients Not in VGPR or Better - FR
CHU de Limoges - Hôpital Dupuytren

Service d'hématologie clinique et de thérapie cellulaire

AMYLCAR : Assessment of Cardiac Fixation During Positron Emission Tomography (PET) Examination Using 18F-Flutemetamol (Vizamyl ®) Within Amyloid Cardiac Injuries (Phase I)
CHU de Toulouse - Hôpital Pierre-Paul Riquet

Service de Médecine nucléaire

ADUSE: Subcutaneous Injections of Autologous Cultured Adipose-derived Stroma/ Stem Cells to Heal Refractory Ischemic Digital Ulcers in Patients With Scleroderma.
CHU de Toulouse - Hôpital Rangueil

Service de Médecine interne et immunologie clinique

SCLERADEC III : SCLERoderma and Adipose-DErived Stroma Cells (Phase II)
CHU de Marseille - Hôpital Nord

Service de Médecine Interne

An open-label, phase 1/2 study of melflufen and dexamethasone for patients with al amyloidosis following at least one prior line of therapy - DE
Zentrum für Innere Medizin (Krehl-Klinik)

Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

ReDox: A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - DE
Zentrum für Innere Medizin (Krehl-Klinik)

Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

A phase 2 study of Belantamab Mafodotin in patients with relapsed or refractory AL amyloidosis -DE
Zentrum für Innere Medizin (Krehl-Klinik)

Medizinische Klinik V - Hämatologie, Onkologie und Rheumatologie

PRESIDIO: A Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients with Active Polymyositis or Dermatomyositis
Institution: Information not provided - DE

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis - DE
Institution: Information not provided - DE

EMERALD: A Two-cohort, Open-label, Single Arm, Multicenter Study to Evaluate Efficacy, Safety and Tolerability, PK and PD, of Emapalumab in Children and Adults With MAS in Still's Disease or With MAS in Systemic Lupus Erythematous - DE
Institution: Information not provided - DE

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE
Charité - Universitätsmedizin Berlin

wiRASSc: Influence of serial locoregional water-filtered infrared A radiation in addition to a multimodal standard therapy for systemic sclerosis and Raynaud's syndrome of the hands
Kerckhoff-Klinik GmbH

Abteilung für Rheumatologie und klinische Immunologie

SENSCIS (TM) Extension: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - DE
Medizinische Hochschule Hannover

Klinik für Pneumologie

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE
Universitätsklinikum Essen

Klinik für Neurologie

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE
Universitätsklinikum Köln

The RECLAIIM Study: A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) in Adults with Dermatomyositis (DM) - DE
Universitätsklinikum Münster

A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis
Institute of Genomic Medicine and Rare Disorders, Semmelweis University

Genetics Laboratory

A Randomized, Double Blind, Placebo Controlled Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan (CCX168) in Patients With C3 Glomerulopathy - IE
Beaumont Hospital

Kidney Centre

SENSCISTM- ON: An open-label extension trial to assess the long term safety of nintedanib in patients with Systemic Sclerosis associated Interstitial Lung Disease (SSc-ILD) - IE
St. Vincent's University Hospital

CF Clinic

EYEGUARD-B: Studio randomizzato, in doppio cieco, controllato verso placebo, dell'efficacia di gevokizumab nel trattamento di pazienti affetti da uveite di Behcet
Institution: Information not provided - IT

A phase 3, multicenter, randomized, doubleblind, placebo-controlled, parallel group study, followed by an active-treatment phase to evaluate the efficacy and safety of Apremilast (CC-10004) in the treatment of subjects with active Behçet's disease - IT
Institution: Information not provided - IT

OFA3: Efficacy of humanized anti-CD20 antibodies (Ofatumumab) in the treatment of childhood steroid-dependent nephrotic syndrome and development of cell biomarkers predicting outcome
Institution: Information not provided - IT

An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy - IT
Institution: Information not provided - IT

A Phase 2/3, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Dermatomyositis - IT
Institution: Information not provided - IT

Efficacy of monoclonal anti CD 20 antibodies in steroid and cyclosporin dependent nephrotic syndrome in children - IT
IRCCS Ospedale Pediatrico Bambino Gesù - SEDE SAN PAOLO

Laboratorio di Nefrologia - Divisione di Nefrologia e Dialisi

Five-year actively controlled clinical trial in new onset juvenile dermatomyositis
IRCCS Istituto G. Gaslini - Ospedale Pediatrico

U.O. Pediatria II

A Randomized Phase II/III Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy - IT
Fondazione IRCCS Policlinico San Matteo

Dipartimento di Medicina Molecolare

ASTIS: High dose immunoablation and autologous hematopoietic stem cell transplantation versus monthly intravenous pulse therapy cyclophosphamide in severe systemic sclerosis (Phase III) - IT
AOU Careggi

Dipartimento di Biomedicina

A Phase II/III, randomized, double-blind, placebo-controlled study and open active-treatment extension study to assess the efficacy and safety of the branch chain amino acids (BCAAs) in polymyositis and dDermatomyositis.
Institution: Information not provided - JP

Randomized, double-blind, parallel group comparison trial of Tocilizumab for colchicine-resistant familial Mediterranean fever
Institution: Information not provided - JP

Clinical trial of rituximab in interstitial lung disease secondary to systemic sclerosis
Institution: Information not provided - JP

Efficacy of Rituximab in Comparison to Continued Corticosteroid Treatment in Idiopathic Nephrotic Syndrome Unresponsive to 8 Weeks of High Dose Prednisone
Radboudumc - Radboud universitair medisch centrum

Afdeling Nierziekten

Levamisole treatment for children with steroid sensitive nephrotic syndrome. An international multi-centre, double-blind, placebo-controlled, randomised trial
Amsterdam UMC, locatie AMC

Polikliniek Kindernefrologie

IMMEDIATE: Intravenous immunoglobulins as early treatment in newly diagnosed idiopathic inflammatory myopathies: a pilot study
Amsterdam UMC, locatie AMC

Afdeling Neurologie

A Phase II, Randomized, Multi-center, Placebo-controlled, Double-blind Study to Investigate the Safety of GS-248, and Efficacy on Raynaud's Phenomenon (RP) and Peripheral Vascular Blood Flow, in Subjects With Systemic Sclerosis (SSc) - NL
Institution: Information not provided - NL

The MANUS Trial: Mesenchymal Stromal Cells for Angiogenesis and Neovascularisation in Digital Ulcers of Systemic Sclerosis (Phase II)
UMC Utrecht - Universitair Medisch Centrum Utrecht

Afdeling Nefrologie

EYEGUARD-B: A Randomized, Double-masked, Placebo-controlled Study of the Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (Phase III) - PT
Institution: Information not provided - PT